Novartis' Ilaris helps reduce patients' symptoms and the frequency of attacks in two rare inflammatory diseases, mid-stage studies showed, as the Swiss drugmaker looks to expand the use of the medicine
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment